Literature DB >> 17581420

Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.

Andres G Chiesa-Vottero1, Anais Malpica, Michael T Deavers, Russell Broaddus, Gerard J Nuovo, Elvio G Silva.   

Abstract

The immunohistochemical expression pattern of p16 in biopsy samples has been useful as part of a panel to distinguish adenocarcinomas arising from the endometrium from those arising from the endocervix. However, no information is available on the expression of p16 in uterine serous carcinoma (USC) or ovarian high-grade serous carcinoma that could be used for diagnostic purposes. Here, we retrospectively analyzed the immunohistochemical expression of p16 in 11 cases of USC (5 pure and 6 mixed with endometrioid adenocarcinoma) and 10 cases of ovarian high-grade serous carcinoma and compared p16 expression with that of p53 in the same samples. p16 was strongly expressed by 100% of tumor cells in all 11 uterine specimens and in 5 of the 10 ovarian specimens; of the other 5 ovarian specimens, 4 showed strong positivity in 20% to 80% of tumor cells, and 1 case showed only weak expression. Positivity for p53 was strong and diffuse (100% of tumor cells) in 5 uterine tumors and in 3 ovarian tumors. p53 expression in 6 of the uterine specimens and 7 of the ovarian specimens was present in fewer tumor cells, of weak intensity, or both. We also performed human papilloma virus (HPV) DNA in situ hybridization in 4 uterine pure serous carcinomas; all 4 were negative. The negative results were confirmed by reverse transcriptase in situ polymerase chain reaction. We conclude that p16, owing to its diffuse expression in USC, should not be interpreted as indicating cervical origin or HPV-induced carcinogenesis; however, p16 may be a better marker (albeit unspecific) than p53 for identifying USC. The overexpression of p16 in USC is unrelated to HPV. Further studies are necessary to determine whether p16 expression is useful in the differential diagnosis of ovarian high-grade serous carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17581420     DOI: 10.1097/01.pgp.0000235065.31301.3e

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  14 in total

1.  A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.

Authors:  Christina S Kong; Andrew H Beck; Teri A Longacre
Journal:  Am J Surg Pathol       Date:  2010-07       Impact factor: 6.394

2.  Stromal p16 expression differentiates endometrial polyp from endometrial hyperplasia.

Authors:  Suzuko Moritani; Shu Ichihara; Masaki Hasegawa; Akari Iwakoshi; Sakae Murakami; Tomoko Sato; Tomomitsu Okamoto; Yoshio Mori; Hajime Kuhara; Steven G Silverberg
Journal:  Virchows Arch       Date:  2012-07-07       Impact factor: 4.064

Review 3.  [Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology].

Authors:  S Lax
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

4.  Expression of p16 in nodular fasciitis: an implication for self-limited and inflammatory nature of the lesion.

Authors:  Ikuo Matsuda; Junko Nakamura; Mizuka Ohkouchi; Yoshitaka Torii; Hiroyuki Futani; Yoshitane Tsukamoto; Seiichi Hirota
Journal:  Int J Clin Exp Pathol       Date:  2019-03-01

Review 5.  How to approach the many faces of endometrioid carcinoma.

Authors:  Anais Malpica
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

6.  Immunophenotype and human papillomavirus status of serous adenocarcinoma of the uterine cervix.

Authors:  Shinichi Togami; Yuko Sasajima; Takahiro Kasamatsu; Rie Oda-Otomo; Satoshi Okada; Mitsuya Ishikawa; Shun-ichi Ikeda; Tomoyasu Kato; Hitoshi Tsuda
Journal:  Pathol Oncol Res       Date:  2014-11-05       Impact factor: 3.201

7.  Grade 1 Endometrioid Carcinoma With an Area of Serous Carcinoma Less than 5% Is More Aggressive than Stage IA Pure-type Grade 1 Endometrioid Carcinoma.

Authors:  Morikazu Miyamoto; Hitoshi Tsuda; Atsushi Sugiura; Tsunekazu Kita; Yoshitaka Kataoka; Kenji Ishii; Kazuya Kudo; Hiroko Matsuura; Hiroki Ishibashi; Hideki Iwahashi; Taira Hada; Rie Suzuki; Masashi Takano
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

8.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

9.  [Endometrial carcinomas and precursor lesions--new aspects].

Authors:  D Schmidt
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

10.  Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages.

Authors:  Tim D Eubank; Ryan D Roberts; Mahmood Khan; Jennifer M Curry; Gerard J Nuovo; Periannan Kuppusamy; Clay B Marsh
Journal:  Cancer Res       Date:  2009-02-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.